StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 3.8 %

Shares of EVOK opened at $4.33 on Wednesday. The firm has a market cap of $6.45 million, a price-to-earnings ratio of -0.39 and a beta of 0.36. The company’s fifty day moving average is $5.15 and its 200-day moving average is $5.46. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $17.40.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.